Dark

VTGN
Vistagen Therapeutics, Inc. Common Stock
stock NASDAQ

Market Open

Jun 30, 2026 3:50:29 PM EDT

0.2200USD-70.408%(-0.5400)41,344,218

0.2200Bid 0.2400Ask 0.0100Spread

Pre-market

Jun 30, 2026 9:29:30 AM EDT

0.2184USD-71.263%(-0.5416)4,013,190

After-hours

Jun 29, 2026 4:44:30 PM EDT

0.7706USD+0.522%(+0.0040)0

OverviewOptionsHistoricalExchangesShortsNews

Nov 16, 2021

08:30AM EST VistaGen Therapeutics to Present at the Jefferies London GlobeNewswire Inc

Nov 10, 2021

06:44PM EST VistaGen Therapeutics Q2 EPS $(0.07) Down From $(0.05) YoY, Sales $358.00K Up From $334.00K YoY Benzinga

Nov 4, 2021

08:00AM EDT VistaGen Therapeutics to Report Fiscal Year 2022 Second Quarter GlobeNewswire Inc

Oct 14, 2021

12:18PM EDT VistaGen Therapeutics Inc. Expands Clinical Development of PH94B with Initiation of Phase 2A AjDA Trial Benzinga

08:07AM EDT VistaGen Therapeutics Expands Clinical Development Of PH94B With Initiation Of Phase 2A Trial In Adjustment Disorder Benzinga

08:00AM EDT Study Launches Phase 2A Clinical Program Designed to Explore PH94Bs Potential in Multiple Additional Anxiety Disorders GlobeNewswire Inc

Oct 5, 2021

08:03AM EDT VistaGen Therapeutics Reports New Preclinical Mechanism Of Action Data; Co Says Data Supports PH94B's Potential Anti-Anxiety Activity Via Peripheral Nasal Neurons Without Entry Into Brain Benzinga

08:00AM EDT VistaGen Therapeutics Reports New Preclinical Mechanism of Action GlobeNewswire Inc

Sep 13, 2021

06:14AM EDT VistaGen Therapeutics Begins PALISADE-2 Trial Of PH94B In Social Anxiety Disorder RTTNews

06:09AM EDT VistaGen Therapeutics Initiates PALISADE-2 Phase 3 Program For PH94B In Social Anxiety Disorder Benzinga

06:00AM EDT VistaGen Therapeutics Further Advances PALISADE Phase 3 Program GlobeNewswire Inc

Sep 8, 2021

08:00AM EDT VistaGen Therapeutics to Participate in Bairds GlobeNewswire Inc

Sep 1, 2021

10:12AM EDT VistaGen Therapeutics Sponsored Study Titled 'Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)' Posted To ClinicalTrials.Gov; Study Not Yet Recruiting Benzinga

Aug 18, 2021

09:40AM EDT VistaGen Therapeutics-Sponsored Study Titled 'PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2 (Palisade-2)' Posted To ClinicalTrials.Gov Website; Study Not Yet Recruiting Benzinga

Aug 12, 2021

05:30PM EDT Recap: VistaGen Therapeutics Q1 Earnings Benzinga

04:48PM EDT VistaGen Therapeutics Q1 EPS $(0.04) Up From $(0.07) YoY, Sales $354.10K Benzinga

Aug 9, 2021

04:05PM EDT VistaGen Therapeutics to Report Fiscal Year 2022 First Quarter GlobeNewswire Inc

Aug 2, 2021

08:00AM EDT VistaGen Therapeutics to Participate in Canaccord Genuity 41st GlobeNewswire Inc

Jul 22, 2021

08:00AM EDT VistaGen Therapeutics Announces Appointment of Maggie FitzPatrick GlobeNewswire Inc

Jul 13, 2021

11:08AM EDT Looking Into VistaGen Therapeutics's Return On Capital Employed Benzinga

Jul 9, 2021

08:30AM EDT VistaGen Therapeutics to Participate in William Blair Biotech GlobeNewswire Inc

Jul 7, 2021

08:39AM EDT VistaGen Therapeutics Appoints Mary Rotunno To Its Board RTTNews

08:30AM EDT VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced the appointment of Mary L. Rotunno, J.D. to its Board of Directors (Board). GlobeNewswire Inc

Jul 6, 2021

01:51PM EDT VistaGen Therapeutics Insights: Return On Capital Employed Benzinga

Jul 2, 2021

07:38AM EDT The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures Benzinga

Jun 30, 2021

01:21PM EDT VistaGen shares are trading higher after the company reported FY21 EPS of $(0.49), up from $(0.50) year over year. Benzinga

Jun 29, 2021

05:37PM EDT VistaGen Therapeutics: Q4 Earnings Insights Benzinga

04:15PM EDT PALISADE-1 Phase 3 trial underway to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) GlobeNewswire Inc

04:15PM EDT VistaGen FY21 EPS $(0.49), Up From $(0.50) YoY Benzinga

04:01AM EDT Earnings Scheduled For June 29, 2021 Benzinga

Jun 25, 2021

08:00AM EDT VistaGen Therapeutics to Report 2021 Fiscal Year End Financial GlobeNewswire Inc

Jun 16, 2021

08:09AM EDT VistaGen Therapeutics Will Join Russell 2000 Index, Effective Jun. 28 Benzinga

08:00AM EDT VistaGen Therapeutics Set to Join the Russell 2000 Index GlobeNewswire Inc

May 26, 2021

09:28AM EDT VistaGen Kick Starts Late-Stage Social Anxiety Disorder Study with PH94B Benzinga

08:07AM EDT VistaGen Therapeutics Initiates PALISADE Phase 3 Trial Of PH94B In Social Anxiety Disorder Benzinga

08:00AM EDT PALISADE Phase 3 Program focused on acute treatment of anxiety in adults with Social Anxiety Disorder GlobeNewswire Inc

May 20, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2021 Benzinga

08:00AM EDT VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (CNS) disorders, today announced that it will present at the following investor conferences in June: GlobeNewswire Inc

06:30AM EDT Baird Initiates Coverage On VistaGen Therapeutics with Outperform Rating, Announces Price Target of $9 Benzinga

May 19, 2021

04:12PM EDT UPDATE: Baird On VistaGen: Calls The Stock 'Significantly Undervalued,' Sees 'this under the radar story as big outperformer over the next year' Benzinga

May 4, 2021

08:00AM EDT VistaGen Therapeutics Announces Appointment of Ann Cunningham as GlobeNewswire Inc

Apr 27, 2021

09:53AM EDT Novel Anxiety and Depression Approach by VistaGen Therapeutics Benzinga

08:00AM EDT VistaGen Therapeutics Announces Appointment of Joanne Curley, Ph.D GlobeNewswire Inc

Mar 26, 2021

04:39PM EDT Highlights From Day 2 Of Benzinga's Biotech Small Cap Conference Benzinga

Mar 22, 2021

08:39AM EDT VistaGen Therapeutics Says Co's Poster Presentation At Anxiety And Depression Association Of America 2021 Conference 'Differentiates PH94B's Mechanism Of Action From Highly-Addictive Benzodiazepines' Benzinga

08:30AM EDT VistaGens Poster Presentation at the Anxiety and GlobeNewswire Inc

Mar 16, 2021

07:46AM EDT VistaGen Therapeutics to Participate in Upcoming Investor GlobeNewswire Inc

Mar 15, 2021

05:11PM EDT VistaGen Therapeutics Announces Offering Of $250M In Shares Of Common Stock Benzinga

Mar 11, 2021

08:37AM EST VistaGen Reports Its PH10 Nasal Spray Showed Different Mechanism Of Action From Benzodiazepines In Preclinical Study Benzinga

08:30AM EST VistaGens PH10 Nasal Spray Demonstrates GlobeNewswire Inc

Feb 23, 2021

07:25AM EST The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga

Feb 18, 2021

10:02AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 18, 2021 Benzinga

06:43AM EST Jefferies Initiates Coverage On VistaGen Therapeutics with Buy Rating, Announces Price Target of $6 Benzinga

Feb 16, 2021

06:41AM EST Acuta Capital Partners, LLC Reported Stake of 5.4% in Vistagen Therapeutics in 13G Filing Benzinga

Feb 11, 2021

04:37PM EST VistaGen Therapeutics Q3 EPS $(0.07) Up From $(0.15) YoY Benzinga

04:30PM EST Multiple clinical studies anticipated to launch in Calendar 2021, notably pivotal Phase 3 clinical studies of PH94B as a potential acute treatment of anxiety in adults with social anxiety disorder (SAD) GlobeNewswire Inc

Jan 26, 2021

08:07AM EST The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market Benzinga

Jan 20, 2021

07:32AM EST The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga

Jan 15, 2021

07:57AM EST The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges Benzinga

Jan 8, 2021

07:25AM EST The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs Benzinga

Jan 6, 2021

08:10AM EST VistaGen Therapeutics Regains Full Compliance With Nasdaq Listing Requirements Benzinga

08:00AM EST VistaGen Therapeutics Regains Full Compliance with Nasdaq Listing GlobeNewswire Inc

Jan 5, 2021

08:39AM EST The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data Benzinga

Jan 4, 2021

10:04AM EST Benzinga's Top Upgrades, Downgrades For January 4, 2021 Benzinga

07:53AM EST William Blair Upgrades VistaGen Therapeutics to Outperform Benzinga

Dec 30, 2020

09:05AM EST VistaGen Reports Publication Of Proposed Mechanism Of Action In Neuroactive Nasal Spray For Anxiety, Depression Disorders Benzinga

09:00AM EST VistaGen Announces Publication in CNS Spectrums Detailing Proposed GlobeNewswire Inc

Dec 23, 2020

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 22, 2020

04:01PM EST VistaGen Therapeutics Announces Closing of $100 Million GlobeNewswire Inc

07:45AM EST The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes Benzinga

Dec 18, 2020

07:48AM EST The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data Benzinga

07:45AM EST The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data Benzinga

06:27AM EST VistaGen Prices 63M Share Common Stock Offering At $0.92/Share Benzinga

06:25AM EST VistaGen Therapeutics Announces Pricing of Underwritten Public GlobeNewswire Inc

Dec 17, 2020

04:01PM EST VistaGen Reports Offering Of Common Stock, Series D Convertible Preferred Stock, No Terms Disclosed Benzinga

04:01PM EST VistaGen Therapeutics Announces Proposed Underwritten Public Offering GlobeNewswire Inc

Dec 10, 2020

08:33AM EST VistaGen Announces Korean Intellectual Property Office Decision To Grant PH10 Patent For Treatment Of Depression Benzinga

08:31AM EST VistaGen Announces Korean Intellectual Property Office Decision to Grant PH10 PR Newswire

Dec 1, 2020

08:31AM EST Ph.D., Pioneer in the Development of Neuroactive Steroids known as Pherines as Potential Treatments for Anxiety and Depression Disorders, as Vice President, Translational Medicine PR Newswire

Nov 12, 2020

05:27PM EST VistaGen Therapeutics Q2 EPS $(0.05) Up From $(0.13) YoY Benzinga

05:26PM EST VistaGen Therapeutics Reports Fiscal 2021 Second Quarter Financial Results and PR Newswire

08:38AM EST VistaGen Reports Positive Data Differentiating Mechanism Of Action Of PH94B From Risk-Ridden Benzodiazepines RTTNews

08:31AM EST VistaGen Reports Positive Preclinical Data Differentiating Mechanism of Action PR Newswire

08:31AM EST VistaGen Reports Positive Preclinical Data Differentiating Mechanism Of Action Of PH94B From Risk-Ridden Benzodiazepines Benzinga

Nov 9, 2020

08:01AM EST VistaGen Therapeutics to Participate in the Guggenheim Healthcare Talks | Idea PR Newswire

Oct 27, 2020

08:17AM EDT via InvestorWire InvestorBrandNetwork(IBN), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode ofThe Stock2Me Podcastas part of its sustained effort to provide specialized content distribution via widespread syndication channels. GlobeNewswire Inc

Oct 14, 2020

08:34AM EDT Nasdaq Grants VistaGen 180-Day Extension To Meet Minimum Bid Price Requirement Benzinga

Oct 8, 2020

12:23PM EDT Aegis Capital Initiates Coverage On VistaGen Therapeutics with Buy Rating, Announces Price Target of $6 Benzinga

Sep 3, 2020

08:38AM EDT VistaGen Reports Positive New Data From Second Preclinical Study Of AV-101 In Combination With Probenecid RTTNews

08:36AM EDT VistaGen Reports New Data From Second Preclinical Study Of AV-101 In Combination With Probenecid Benzinga

08:31AM EDT VistaGen Reports Positive New Data from Second Preclinical Study of AV-101 in PR Newswire

Aug 27, 2020

08:31AM EDT VistaGen Therapeutics to Present at the LD Micro 500 Virtual Conference PR Newswire

Aug 13, 2020

04:35PM EDT VistaGen Therapeutics Q1 EPS $(0.07) Up From $(0.15) YoY Benzinga

04:31PM EDT VistaGen Therapeutics Reports Fiscal 2021 First Quarter Financial Results and PR Newswire

Aug 10, 2020

08:31AM EDT VistaGen Therapeutics Announces Exercise and Closing of Underwriters' PR Newswire

Aug 5, 2020

05:18PM EDT VistaGen Therapeutics Announces The Closing Of Its 15.625M Share Common Stock Offering At $0.80 per share Benzinga

04:31PM EDT VistaGen Therapeutics Announces Closing of $12.5 Million Underwritten Public PR Newswire

Aug 4, 2020

08:07AM EDT VistaGen Therapeutics Announces Receipt Of $5M Non-Dilutive Upfront License Payments From EverInsight Therapeutics For PH94B Strategic Collaboration Benzinga

08:02AM EDT License Payment from EverInsight Therapeutics for PH94B Strategic Collaboration PR Newswire

Aug 3, 2020

02:35PM EDT Mid-Afternoon Market Update: Dow Surges 260 Points; Varian Medical Systems Shares Climb Benzinga

12:06PM EDT Mid-Day Market Update: Crude Oil Rises 2%; ADT Shares Spike Higher Benzinga

05:49AM EDT VistaGen Therapeutics Prices 15.6M Share Underwritten Public Offering of Common Stock @$0.80/Share Benzinga

Aug 2, 2020

08:44PM EDT VistaGen Therapeutics Prices Underwritten Public Offering Of 15.63 Mln Shares At $0.80/shr RTTNews

08:00PM EDT VistaGen Therapeutics Announces Pricing of $12.5 Million Underwritten Public PR Newswire

Jul 31, 2020

04:21PM EDT VistaGen Therapeutics Announces Proposed Public Offering Of Common Stock; Size Not Disclosed Benzinga

04:19PM EDT VistaGen Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire

Jul 23, 2020

09:13AM EDT Hearing Maxim Raises Price Target On VistaGen Therapeutics To $3 Benzinga

08:12AM EDT VistaGen Therapeutics Announces Positive Meeting With FDA Regarding Pivotal Phase 3 Study Of PH94B RTTNews

08:05AM EDT VistaGen Therapeutics Announces Positive Meeting With FDA Regarding Pivotal Phase 3 Study Of PH94B For Acute Treatment Of Anxiety In Patients With Social Anxiety Disorder; Says Co. And FDA 'reached consensus on key aspects' Benzinga